Healthcare / Medical DevicesKOSDAQ
$6990.00
-140.00 (-2.02%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-6.2B · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$74.0B
P/E
N/A
•EV/EBITDA
53.8x
↑ROE
-4.7%
↓Gross Margin
45.5%
↓Debt/Equity
0.73
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.8%
FCF CAGR
—
FCF margin
4.3%
FCF / Net income
-1.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $118.04B · net income $-4.97B · FCF $5.04B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $118.04B | $118.04B | $117.88B | $117.74B | $108.78B |
| Net Income | $-4.97B | $-4.97B | $8.71B | $9.98B | $17.08B |
| EBITDA | $2.66B | $2.66B | $16.10B | $17.05B | $24.84B |
| EPS | -461.00 | -461.00 | 800.00 | 928.00 | 1611.00 |
| Gross Margin | 45.5% | 45.5% | 47.1% | 45.0% | 46.1% |
| Operating Margin | 4.7% | 4.7% | 11.3% | 13.9% | 18.5% |
| Net Margin | -4.2% | -4.2% | 7.4% | 8.5% | 15.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.73 | 0.73 | 0.58 | 0.50 | 0.43 |
| Current Ratio | 1.08 | 1.08 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $5.04B | $5.04B | $-11.84B | $-6.17B | $-2.68B |
| Returns | |||||
| ROE | -4.7% | -4.7% | 7.5% | 9.0% | 16.6% |
| Valuation | |||||
| P/E | — | — | 10.31 | 20.96 | 6.27 |
| EV/EBITDA | 53.80 | 53.80 | 9.25 | 15.08 | 5.76 |
| P/B | 0.71 | 0.71 | 0.78 | 1.89 | 1.04 |
| Growth & Yield | |||||
| Revenue Growth | 0.1% | 0.1% | 0.1% | 8.2% | — |
| EPS Growth | -157.6% | -157.6% | -13.8% | -42.4% | — |
| Dividend Yield | 3.7% | 3.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-8.0%
Start / end P/E
n/dx → n/dx
EPS bridge
800.00 → -461.00
Residual
-11.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.